Effects of latanoprost 50 μg/ml on Chinese patients with primary open- angle glaucoma and ocular hypertension

Catherine Jui Ling Liu, Joe Ching Kuang Chou, Wen-Ming Hsu, Jorn Hon Liu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background. This study was designed to determine the efficacy and safety of latanoprost 50 μg/ml in Chinese patients with primary open-angle glaucoma (POAG) and ocular hypertension (OH). Methods. A 14-day randomized, double- masked, parallel-group study comparing topical latanoprost with placebo was followed by a 10-week, one-armed, open-labeled latanoprost treatment study. Intraocular pressure (IOP), visual function, ocular manifestations and miscellaneous adverse effects were evaluated at baseline, and days 1, 7, 14, 15, week 6 and week 12 visits. Results. Twenty-six eligible patients were enrolled in the study. The mean IOP was significantly reduced from baseline only in the latanoprost-treated eyes during the first study period (p = 0.003 on day 1; p = 0.004 on day 7; p < 0.001 on day 14). Meanwhile, the mean IOP was significantly lower in the latanoprost-treated eyes than that in the placebo-treated eyes (p = 0.03 on day 1; p = 0.001 on days 7 and 14). Eyes in both groups showed significantly reduced IOP at each visit of the secondary 10-week latanoprost treatment period, with a mean decrease of 6.12 mmHg. The IOP-lowering effect showed no diminution throughout the study course. Conjunctival hyperemia occurred in 16 of all patients who underwent latanoprost treatment and was the most frequent adverse effect observed. No patient withdrew from the study because of intolerable side-effects. Conclusions. Topical latanoprost is effective in reducing IOP for patients with POAG and OH. The pressure-lowering effect lasts for at least 24 hours after 1 drop instillation and no drift of effect is noted during this 12-week study. Conjunctival hyperemia was the most common side-effect, which was mild in degree and recovered after discontinuation of the medication.

Original languageEnglish
Pages (from-to)703-709
Number of pages7
JournalChinese Medical Journal (Taipei)
Volume62
Issue number10
Publication statusPublished - Oct 1 1999
Externally publishedYes

Fingerprint

latanoprost
Ocular Hypertension
Intraocular Pressure
Hyperemia
Eye Manifestations
Placebos
Primary Open Angle Glaucoma

Keywords

  • Glaucoma
  • Intraocular pressure
  • Latanoprost
  • Ocular hypertension
  • Prostaglandin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of latanoprost 50 μg/ml on Chinese patients with primary open- angle glaucoma and ocular hypertension. / Liu, Catherine Jui Ling; Chou, Joe Ching Kuang; Hsu, Wen-Ming; Liu, Jorn Hon.

In: Chinese Medical Journal (Taipei), Vol. 62, No. 10, 01.10.1999, p. 703-709.

Research output: Contribution to journalArticle

Liu, Catherine Jui Ling ; Chou, Joe Ching Kuang ; Hsu, Wen-Ming ; Liu, Jorn Hon. / Effects of latanoprost 50 μg/ml on Chinese patients with primary open- angle glaucoma and ocular hypertension. In: Chinese Medical Journal (Taipei). 1999 ; Vol. 62, No. 10. pp. 703-709.
@article{7a9ca9a952f84e90a079f6593ddd9442,
title = "Effects of latanoprost 50 μg/ml on Chinese patients with primary open- angle glaucoma and ocular hypertension",
abstract = "Background. This study was designed to determine the efficacy and safety of latanoprost 50 μg/ml in Chinese patients with primary open-angle glaucoma (POAG) and ocular hypertension (OH). Methods. A 14-day randomized, double- masked, parallel-group study comparing topical latanoprost with placebo was followed by a 10-week, one-armed, open-labeled latanoprost treatment study. Intraocular pressure (IOP), visual function, ocular manifestations and miscellaneous adverse effects were evaluated at baseline, and days 1, 7, 14, 15, week 6 and week 12 visits. Results. Twenty-six eligible patients were enrolled in the study. The mean IOP was significantly reduced from baseline only in the latanoprost-treated eyes during the first study period (p = 0.003 on day 1; p = 0.004 on day 7; p < 0.001 on day 14). Meanwhile, the mean IOP was significantly lower in the latanoprost-treated eyes than that in the placebo-treated eyes (p = 0.03 on day 1; p = 0.001 on days 7 and 14). Eyes in both groups showed significantly reduced IOP at each visit of the secondary 10-week latanoprost treatment period, with a mean decrease of 6.12 mmHg. The IOP-lowering effect showed no diminution throughout the study course. Conjunctival hyperemia occurred in 16 of all patients who underwent latanoprost treatment and was the most frequent adverse effect observed. No patient withdrew from the study because of intolerable side-effects. Conclusions. Topical latanoprost is effective in reducing IOP for patients with POAG and OH. The pressure-lowering effect lasts for at least 24 hours after 1 drop instillation and no drift of effect is noted during this 12-week study. Conjunctival hyperemia was the most common side-effect, which was mild in degree and recovered after discontinuation of the medication.",
keywords = "Glaucoma, Intraocular pressure, Latanoprost, Ocular hypertension, Prostaglandin",
author = "Liu, {Catherine Jui Ling} and Chou, {Joe Ching Kuang} and Wen-Ming Hsu and Liu, {Jorn Hon}",
year = "1999",
month = "10",
day = "1",
language = "English",
volume = "62",
pages = "703--709",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "10",

}

TY - JOUR

T1 - Effects of latanoprost 50 μg/ml on Chinese patients with primary open- angle glaucoma and ocular hypertension

AU - Liu, Catherine Jui Ling

AU - Chou, Joe Ching Kuang

AU - Hsu, Wen-Ming

AU - Liu, Jorn Hon

PY - 1999/10/1

Y1 - 1999/10/1

N2 - Background. This study was designed to determine the efficacy and safety of latanoprost 50 μg/ml in Chinese patients with primary open-angle glaucoma (POAG) and ocular hypertension (OH). Methods. A 14-day randomized, double- masked, parallel-group study comparing topical latanoprost with placebo was followed by a 10-week, one-armed, open-labeled latanoprost treatment study. Intraocular pressure (IOP), visual function, ocular manifestations and miscellaneous adverse effects were evaluated at baseline, and days 1, 7, 14, 15, week 6 and week 12 visits. Results. Twenty-six eligible patients were enrolled in the study. The mean IOP was significantly reduced from baseline only in the latanoprost-treated eyes during the first study period (p = 0.003 on day 1; p = 0.004 on day 7; p < 0.001 on day 14). Meanwhile, the mean IOP was significantly lower in the latanoprost-treated eyes than that in the placebo-treated eyes (p = 0.03 on day 1; p = 0.001 on days 7 and 14). Eyes in both groups showed significantly reduced IOP at each visit of the secondary 10-week latanoprost treatment period, with a mean decrease of 6.12 mmHg. The IOP-lowering effect showed no diminution throughout the study course. Conjunctival hyperemia occurred in 16 of all patients who underwent latanoprost treatment and was the most frequent adverse effect observed. No patient withdrew from the study because of intolerable side-effects. Conclusions. Topical latanoprost is effective in reducing IOP for patients with POAG and OH. The pressure-lowering effect lasts for at least 24 hours after 1 drop instillation and no drift of effect is noted during this 12-week study. Conjunctival hyperemia was the most common side-effect, which was mild in degree and recovered after discontinuation of the medication.

AB - Background. This study was designed to determine the efficacy and safety of latanoprost 50 μg/ml in Chinese patients with primary open-angle glaucoma (POAG) and ocular hypertension (OH). Methods. A 14-day randomized, double- masked, parallel-group study comparing topical latanoprost with placebo was followed by a 10-week, one-armed, open-labeled latanoprost treatment study. Intraocular pressure (IOP), visual function, ocular manifestations and miscellaneous adverse effects were evaluated at baseline, and days 1, 7, 14, 15, week 6 and week 12 visits. Results. Twenty-six eligible patients were enrolled in the study. The mean IOP was significantly reduced from baseline only in the latanoprost-treated eyes during the first study period (p = 0.003 on day 1; p = 0.004 on day 7; p < 0.001 on day 14). Meanwhile, the mean IOP was significantly lower in the latanoprost-treated eyes than that in the placebo-treated eyes (p = 0.03 on day 1; p = 0.001 on days 7 and 14). Eyes in both groups showed significantly reduced IOP at each visit of the secondary 10-week latanoprost treatment period, with a mean decrease of 6.12 mmHg. The IOP-lowering effect showed no diminution throughout the study course. Conjunctival hyperemia occurred in 16 of all patients who underwent latanoprost treatment and was the most frequent adverse effect observed. No patient withdrew from the study because of intolerable side-effects. Conclusions. Topical latanoprost is effective in reducing IOP for patients with POAG and OH. The pressure-lowering effect lasts for at least 24 hours after 1 drop instillation and no drift of effect is noted during this 12-week study. Conjunctival hyperemia was the most common side-effect, which was mild in degree and recovered after discontinuation of the medication.

KW - Glaucoma

KW - Intraocular pressure

KW - Latanoprost

KW - Ocular hypertension

KW - Prostaglandin

UR - http://www.scopus.com/inward/record.url?scp=0032863744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032863744&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 703

EP - 709

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 10

ER -